Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 09, 2024 08:00 ET | Source: BioAtla, Inc.

BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
August 28, 2024 08:00 ET | Source: BioAtla, Inc.

BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
August 08, 2024 16:05 ET | Source: BioAtla, Inc.

Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress

Ozuriftamab vedotin (CAB-ROR2-ADC) granted Fast Track Designation by FDA in squamous cell carcinoma of the head and neck (SCCHN); anticipate FDA meeting for SCCHN potential registrational trial in 2H...
August 01, 2024 08:00 ET | Source: BioAtla, Inc.

BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024

SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
July 25, 2024 17:39 ET | Source: BioAtla, Inc.

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

Clinical benefit observed among non-small cell lung cancer (NSCLC) patients harboring mutant KRAS (mKRAS) variants in the Phase 2 mecbotamab vedotin (CAB-AXL-ADC) study; AXL tumoral expression highly...
July 23, 2024 08:00 ET | Source: BioAtla, Inc.

BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Ozuriftamab vedotin, the Company’s conditionally and reversibly active antibody drug conjugate directed against ROR2, has shown promising clinical activity with a manageable safety profile in...
June 27, 2024 08:00 ET | Source: BioAtla, Inc.

BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024

SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
May 29, 2024 08:00 ET | Source: BioAtla, Inc.

BioAtla to Participate in the Jefferies Global Healthcare Conference

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
May 23, 2024 17:05 ET | Source: BioAtla, Inc.

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Multiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving evalstotug High doses of evalstotug as...
May 14, 2024 16:05 ET | Source: BioAtla, Inc.

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 data in squamous cell carcinoma of the head and neck (SCCHN) showed multiple confirmed responses and manageable safety profile; anticipate FDA meeting for...